Join/ Subscribe

Subscribe

We recognize the significance of content in the modern digital world. Sign up on our website to receive the most recent technology trends directly in your email inbox..


Safe and Secure

Free Articles

Join/ Subscribe Us

Subscribe

We recognize the significance of content in the modern digital world. Sign up on our website to receive the most recent technology trends directly in your email inbox.





    We assure a spam-free experience. You can update your email preference or unsubscribe at any time and we'll never share your information without your consent. Click here for Privacy Policy.


    Safe and Secure

    Free Articles

    HealthTech

    KnowledgeNile is the one of the emerging technology content marketing organizations. 

    '}}
    Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
    CAMBRIDGE, Mass.,(GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company’s VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which […]
    '}}
    Novotech Appoints Dr. Yooni Kim as a New Executive Position of Managing Director for APAC to Strengthen Global Expansion
    Business Wire India Novotech, the leading global biotech Contract Research Organization (CRO), is pleased to announce the appointment of Dr. Yooni Kim as a new Executive position of Managing Director for the Asia-Pacific (APAC) region, effective September 1, 2024. This strategic appointment is part of Novotech's ongoing efforts to expand its global footprint and enhance […]
    '}}
    CHMP has adopted a negative opinion on lecanemab for the EU
    STOCKHOLM, July 26, 2024 -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has today communicated that it has adopted a negative opinion on BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai's Marketing Authorization Approval (MAA) for lecanemab as treatment for Alzheimer's disease. BioArctic is currently consulting […]
    Scroll to Top